Eglatoprutug Biosimilar - Research Grade

Human

KIT

>1mg/ml

IgG1 - kappa

CHO Cells

Barzolvolimab Biosimilar - Research Grade (ICH5374), Briquilimab Biosimilar - Research Grade (ICH5415), Opelkibart Biosimilar - Research Grade (ICH5737)

https://www.imgt.org/mAb-DB/

ICH3002

P10721

3815

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of eglatoprutug, an anti-KIT (CD117) monoclonal antibody, supplied for research use only. It is built around the same human KIT target and expressed as a human IgG1/kappa framework, but it is not the clinical drug and is not intended for human or veterinary use. The recombinant format makes it a useful tool for laboratories studying KIT biology and for teams developing or benchmarking KIT-directed reagents. Typical research applications include use as an isotype-matched binding and specificity control, characterization of KIT expression on cell lines and primary cells, ligand/receptor blocking assays, and as a reference antibody during assay development, antibody-drug-conjugate (ADC) work, or Fc-effector studies. It is manufactured as a low-endotoxin research-grade preparation (<1 EU/mg; ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities suitable for scaled in-vitro workflows and preclinical standards. Because it is offered as a well-defined recombinant analog, it supports reproducible, cost-effective experimentation where consistent lot-to-lot performance matters. KIT (CD117, stem cell factor receptor; UniProt P10721) is a type III receptor tyrosine kinase composed of five extracellular immunoglobulin-like domains, a single transmembrane region, and a split intracellular kinase domain. Its ligand, stem cell factor (SCF), drives receptor dimerization, trans-autophosphorylation, and activation of downstream PI3K/AKT, RAS/MAPK, and JAK/STAT signaling. KIT is essential for hematopoietic stem and progenitor cells, mast cells, melanocytes, germ cells, and interstitial cells of Cajal, regulating survival, proliferation, and differentiation. Activating KIT mutations and overexpression are implicated in gastrointestinal stromal tumors (GIST), systemic mastocytosis, acute myeloid leukemia, and melanoma, making KIT a well-validated oncology and mast-cell-disease target. As a cell-surface receptor, KIT is readily accessible to antibody-based detection and functional blockade.

SCFR, Piebald trait protein, PBT, Proto-oncogene c-Kit, Tyrosine-protein kinase Kit, p145 c-kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, Mast/stem cell growth factor receptor Kit

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Eglatoprutug (anti-KIT) Biosimilar

Q: Is the Eglatoprutug biosimilar available in bulk or gram quantities?

A: Yes — the Eglatoprutug biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Eglatoprutug suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Eglatoprutug biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Eglatoprutug that binds KIT.